- Home
- IONS vs SUN Comparison
IONS vs SUN Comparison
Compare IONS & SUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- SUN
- Stock Information
- Founded
- IONS 1989
- SUN 1886
- Country
- IONS United States
- SUN United States
- Employees
- IONS N/A
- SUN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- SUN Integrated oil Companies
- Sector
- IONS Health Care
- SUN Energy
- Exchange
- IONS Nasdaq
- SUN Nasdaq
- Market Cap
- IONS 6.9B
- SUN 7.3B
- IPO Year
- IONS 1991
- SUN N/A
- Fundamental
- Price
- IONS $43.78
- SUN $52.36
- Analyst Decision
- IONS Buy
- SUN Buy
- Analyst Count
- IONS 14
- SUN 4
- Target Price
- IONS $58.43
- SUN $64.75
- AVG Volume (30 Days)
- IONS 2.0M
- SUN 372.6K
- Earning Date
- IONS 07-30-2025
- SUN 08-06-2025
- Dividend Yield
- IONS N/A
- SUN 6.93%
- EPS Growth
- IONS N/A
- SUN N/A
- EPS
- IONS N/A
- SUN 2.04
- Revenue
- IONS $944,050,000.00
- SUN $21,589,000,000.00
- Revenue This Year
- IONS $9.21
- SUN $9.82
- Revenue Next Year
- IONS $14.35
- SUN $7.07
- P/E Ratio
- IONS N/A
- SUN $25.70
- Revenue Growth
- IONS 16.05
- SUN N/A
- 52 Week Low
- IONS $23.95
- SUN $48.00
- 52 Week High
- IONS $50.43
- SUN $59.88
- Technical
- Relative Strength Index (RSI)
- IONS 60.61
- SUN 46.54
- Support Level
- IONS $40.37
- SUN $50.45
- Resistance Level
- IONS $41.93
- SUN $54.65
- Average True Range (ATR)
- IONS 1.42
- SUN 1.23
- MACD
- IONS -0.03
- SUN -0.13
- Stochastic Oscillator
- IONS 66.61
- SUN 36.87
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About SUN Sunoco LP Common Units representing limited partner interests
Sunoco LP is engaged in the distribution of motor fuels to independent dealers, distributors, and other commercial customers as well as the distribution of motor fuels to end-use customers at retail sites operated by commission agents. It is a growth-oriented master limited partnership (MLP) that operates as a wholesale and retail fuel distributor in the United States. The firm operates through the Fuel Distribution; Pipeline Systems; and Terminals segments. It generates the majority of its revenue from the Fuel Distribution segment. It distributes motor fuel to convenience stores, dealers, and commercial customers in various states. The operating convenience stores are under the APlus, Stripes, Aloha Island Mart, and Tigermarket brands.